Lesson plan

RNF128

E3 ubiquitin-protein ligase RNF128 is an enzyme that in humans is encoded by the RNF128 gene. The protein encoded by this gene is a type I transmembrane protein that localizes to the endocytic pathway. This protein contains a RING zinc-finger motif and has been shown to possess E3 ubiquitin ligase activity. Expression of this gene in retrovirally transduced T cell hybridoma significantly inhibits activation-induced IL2 and IL4 cytokine production. Induced expression of this gene was observed in anergic CD4 + T cells, which suggested a role in the induction of anergic phenotype. Alternatively spliced transcript variants encoding distinct isoforms have been reported. E3 ubiquitin-protein ligase RNF128 is highly expressed in the liver, adrenal glands, and intestines and also has notable expression in the kidneys, stomach, bladder, and thyroid. This protein lies in the endocytic pathway and contains a signal peptide, a RING zinc-finger motif, a protease associated domain, and a transmembrane domain.

Back to article

Article summary

E3 ubiquitin-protein ligase RNF128 is an enzyme that in humans is encoded by the RNF128 gene. The protein encoded by this gene is a type I transmembrane protein that localizes to the endocytic pathway. This protein contains a RING zinc-finger motif and has been shown to possess E3 ubiquitin ligase activity. Expression of this gene in retrovirally transduced T cell hybridoma significantly inhibits activation-induced IL2 and IL4 cytokine production. Induced expression of this gene was observed in anergic CD4 + T cells, which suggested a role in the induction of anergic phenotype. Alternatively spliced transcript variants encoding distinct isoforms have been reported. E3 ubiquitin-protein ligase RNF128 is highly expressed in the liver, adrenal glands, and intestines and also has notable expression in the kidneys, stomach, bladder, and thyroid. This protein lies in the endocytic pathway and contains a signal peptide, a RING zinc-finger motif, a protease associated domain, and a transmembrane domain.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.